Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

American Society of Clinical Oncology (ASCO) - Tập 22 Số 18 - Trang 3751-3757 - 2004
Angela Dispenzieri1, Morie A. Gertz1, Robert A. Kyle1, Martha Q. Lacy1, Mary F. Burritt1, Terry M. Therneau1, Philip R. Greipp1, Thomas E. Witzig1, John A. Lust1, S. Vincent Rajkumar1, Rafaël Fonseca1, Steven R. Zeldenrust1, Christopher G.A. McGregor1, Allan S. Jaffe1
1From the Division of Hematology and Internal Medicine, the Division of Biostatistics, the Division of Cardiovascular Diseases and Internal Medicine, the Division of Laboratory Genetics and Laboratory Medicine and Pathology, the Department of Surgery, and the Division of Clinical Biochemistry and Immunology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Tóm tắt

Purpose Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL. Patients and Methods Two hundred forty-two patients with newly diagnosed AL who were seen at the Mayo Clinic between April 1979 and November 2000, and who had echocardiograms and stored serum samples at presentation were eligible for this retrospective review. NT-proBNP measurements were performed on 242 patients in whom cTnT and cardiac troponin I (cTnI) had been previously run. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT < 0.035 μg/L, and cTnI < 0.1 μg/L). Depending on whether NT-proBNP and troponin levels were both low, were high for only one level, or were both high, patients were classified as stage I, II, or III, respectively. Results Using the cTnT+NT-proBNP model 33%, 30%, and 37% of patients were stages I, II, and III, respectively, with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI+NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusion Stratification of AL patients into three stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes.

Từ khóa


Tài liệu tham khảo

10.1016/S0735-1097(85)80475-7

10.1016/S0049-0172(05)80006-X

10.1161/01.CIR.83.3.808

Tei C, Dujardin KS, Hodge DO, et al: Doppler index combining systolic and diastolic myocardial performance: Clinical value in cardiac amyloidosis. J Am Coll Cardiol 28:658,1996-664,

10.1016/S0002-9149(97)00400-1

10.1182/blood.V68.1.220.bloodjournal681220

10.1016/0167-5273(90)90053-8

10.1093/qjmed/91.2.141

10.1046/j.1365-2141.1998.00772.x

10.1016/S0002-9343(02)01208-1

10.1038/sj.bmt.1703200

10.1182/blood.V93.3.1062

Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45,1995-59,

10.1016/S0140-6736(03)13396-X

10.1161/01.CIR.0000068314.02595.B2

10.1161/01.CIR.102.11.1216

10.1016/S0002-9149(01)01877-X

10.1067/mhj.2002.124048

10.1016/S0002-9149(03)00741-0

10.1136/heart.89.7.745

10.1046/j.1365-2141.1999.01216.x

10.1002/ajh.2830340112

10.1002/ajh.2830440210

10.1002/(SICI)1096-8652(199906)61:2<115::AID-AJH7>3.0.CO;2-I

10.1007/BF02785843

10.1038/sj.bmt.1702005

10.1046/j.1365-2141.2002.03541.x

10.3109/13506120209072441

10.1073/pnas.92.7.2959

10.1200/JCO.2001.19.14.3350

10.1182/blood.V83.5.1165.1165

10.1056/NEJM199811193392104

10.1182/blood.V89.6.2079

Masson S, Vago T, Baldi G, et al: Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 40:761,2002-763,

10.1016/S0009-8981(01)00578-2

Dispenzieri A, Gertz MA, Kyle RA, et al: Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood (in press)

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 22 Số 18

3751-3757

Thông tin tác giả